Alpha adrenoceptor antagonists in the year 2000: Is there anything new?

Current Opinion in Urology

Volumn 11, Issue 1, 2001, Pages 9-16

  Chapple, C R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; PRAZOSIN; RECEPTOR SUBTYPE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; APOPTOSIS; ASTHENIA; BLADDER NECK STENOSIS; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HEADACHE; HUMAN; LIGAND BINDING; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RECEPTOR BINDING; REVIEW; URETHRA DISEASE; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; APOPTOSIS; HUMANS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA; URINARY BLADDER; URINARY BLADDER NECK OBSTRUCTION;

EID: 0035153447     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200101000-00002     Document Type: Review

References (80)

1. Recommendations of the International Scientific Committee: The evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstrution
2. Outcome analysis of minimally invasive treatments for benign prostatic hyperplasia
3. Medical therapy and quality of life
4. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck
5. A placebo-controlled double-blind study on the effect of phenoxybenzamine in benign prostatic obstruction
6. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia
7. Modulation of the differentiation status of cultured prostatic smooth muscle cells by an alpha1-adrenergic receptor antagonist
8. Influence of the alpha1-adrenergic antagonist, doxazosin, on noradrenaline-induced modulation of cytoskeletal proteins in cultured hyperplastic prostatic stromal cells
9. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation
10. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy
11. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia
12. Alpha-1 adrenoceptors in human prostate: Characterization and alteration in benign prostatic hypertrophy
13. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation
14. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in hyperplastic human prostate
15. Characterisation and localisation of prostatic alpha1 adrenoceptors using radioligand receptor binding on slide mounted tissue section
16. The alpha-adrenoceptor subtype mediating tension of human prostatic smooth muscle
17. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: Comparison of benign hypertrophied tissue and non-hypertrophied tissue
18. Multidirectional contraction of human hypertrophied prostate
19. 1 Adrenoceptor subtypes in the human prostate and inferior epigasfric artery
20. 1 adrenoceptors in human prostate and aorta
21. 1a-adrenergic receptor
22. 1-adrenergic receptor
23. 1-adrenergic receptor subtype
24. 1d adrenergic receptor cDNA
25. 1-adrenoceptor subtypes: Selective antagonists suggest the existence of a fourth subtype
26. 1-adrenoceptor functional classification in prostate
27. Alpha1-adrenoceptor subtypes in the human prostate
28. 1C subtype
29. 1 adrenergic receptor
30. 1b adrenergic receptor
31. 1c adrenergic receptor
32. 1-Adrenoceptor classification: Sharpening Occam's razor
33. Identification, quantification, and localization of mRNA for three distinct alpha1 adrenergic receptor subtypes in human prostate
34. Differential expression of alpha1-adrenergic receptor subtypes in BPH determined by reverse transcriptase PCR (polymerase chain reaction)
35. 3H]tamsulosin in human hypertrophied prostate using computerized image analysis
36. Alpha1-adrenoceptors in human prostate: Characterization and binding characteristics of alpha1-antagonists
37. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery
38. Do alpha-1A (alpha-1C)-adrenoceptors (AR) mediate prostatic smooth muscle contraction in man? Studies with a novel, selective alpha-1A-AR antagonist, RS 17053
39. 1-adrenoceptors in human prostate: Implications for adrenoceptor classification
40. 1-adrenoceptor subtypes in the human prostate: Functional and binding studies
41. 3H] tamsulosin
42. Human cloned alpha1A-adrenoceptor isoforms display alpha1L-adrenoceptor pharmacology in functional studies
43. 1A adrenoceptor: Implications for receptor classification
44. 1 adrenoceptor
45. Pharmacological characterisation of the uroselective alpha 1 antagonist Rec 15/2739 (SB 216469): Role of the alpha-1L adrenoceptor in tissue selectivity, part 11
46. 1-adrenoceptors: Consensus update
47. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate
48. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues
49. Adrenergic response of bladder muscle in prostatic obstruction
50. In vitro response of human bladder smooth muscle in unstable obstructed male bladders: A study of pathophysiological causes
51. Identification of receptor subtypes in the rabbit and human urinary bladder by selective radio-ligand binding
52. Localization of mRNA and receptor binding sites for the alpha 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate
53. Alpha1-adrenergic receptor subtypes in human detrusor
54. Effects of a highly selective alpha-1A antagonist on urinary flow rate in men with symptomatic BPH
55. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats
56. The spontaneously hypertensive rat: Insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males
57. 1 adrenoceptor subtype-specific blockade
58. 1-adrenergic blocking drugs
59. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia)
60. Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia
61. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: The Hypertension and BPH Intervention Trial (HABIT)
62. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: A combined analysis
63. 1-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: A pooled analysis of seven double-blind, placebo-controlled studies
64. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-tomoderate hypertension
65. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia
66. The mechanism of adverse events associated with terazosin: An analysis of the Veterans Affairs Cooperative Study
67. Orally administered alfuzosin has a high prostatic diffusion in benign prostatic hyperplasia
68. Bladder outflow obstruction treated with phenoxybenzamine
69. Bladder outflow obstruction treated with phenoxybenzamine
70. Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia. A urodynamic investigation
71. Ineffectiveness of phenoxybenzamine in treatment of benign prostatic hypertrophy. A controlled study
72. Urinary incontinence caused by prazosin
73. Prazosin in the treatment of prostatic obstruction: A placebo-controlled study
74. Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms
75. Dynamics of acute retention in prostatic patient and role of adrenergic receptors
76. Acute retention of urine due to benign prostatic obstruction treated with alpha-adrenergic blockers
77. Sustained-release alfuzosin and trial without catheter after acute urinary retention: A prospective, placebo-controlled trial
78. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone
79. Alpha blockers and congestive heart failure; early termination of an arm of the ALLHAT Trial